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Hypomethylation of smoking-related genes
is associated with future lung cancer in four
prospective cohorts
Francesca Fasanelli1,2,*, Laura Baglietto3,4,5,6,*, Erica Ponzi1, Florence Guida7, Gianluca Campanella7,
Mattias Johansson8,9, Kjell Grankvist9, Mikael Johansson10, Manuela Bianca Assumma1, Alessio Naccarati1,
Marc Chadeau-Hyam7, Ugo Ala11, Christian Faltus12, Rudolf Kaaks13,14, Angela Risch12,14,15, Bianca De Stavola16,
Allison Hodge5, Graham G. Giles5,6, Melissa C. Southey17, Caroline L. Relton18, Philip C. Haycock18, Eiliv Lund19,
Silvia Polidoro1, Torkjel M. Sandanger19,**, Gianluca Severi1,3,4,5,6,** & Paolo Vineis1,7,**
DNA hypomethylation in certain genes is associated with tobacco exposure but it is unknown
whether these methylation changes translate into increased lung cancer risk. In an
epigenome-wide study of DNA from pre-diagnostic blood samples from 132 case–control
pairs in the NOWAC cohort, we observe that the most signiﬁcant associations with lung
cancer risk are for cg05575921 in AHRR (OR for 1 s.d.¼0.37, 95% CI: 0.31–0.54,
P-value¼ 3.3 10 11) and cg03636183 in F2RL3 (OR for 1 s.d.¼0.40, 95% CI: 0.31–0.56,
P-value¼ 3.9 10 10), previously shown to be strongly hypomethylated in smokers. These
associations remain signiﬁcant after adjustment for smoking and are conﬁrmed in additional
664 case–control pairs tightly matched for smoking from the MCCS, NSHDS and EPIC HD
cohorts. The replication and mediation analyses suggest that residual confounding is unlikely
to explain the observed associations and that hypomethylation of these CpG sites may
mediate the effect of tobacco on lung cancer risk.
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D
NA methylation has recently emerged as an important
marker of current and past smoking habits1–9. Smoking is
a leading cause of death worldwide10,11 and has been
identiﬁed as a major risk factor for several diseases including
cancer12,13, cardiovascular14,15 and respiratory diseases16,17. The
carcinogenic effect of tobacco smoking persists for decades after
smoking cessation, and former smokers remain at increased risk
of lung cancer for 20 years or longer18–20.
Using an epigenome-wide methylation study approach, we
previously demonstrated that tobacco smoking alters DNA
methylation patterns, particularly in CpG sites of the AHRR
and F2RL3 genes7. These results have been extensively replicated
by other studies1–6,8. In particular, our previous study of 1,000
healthy subjects from the EPIC and Norwegian Women and
Cancer (NOWAC) cohorts indicated that smokers had 19% lower
methylation levels at the AHRR CpG site cg05575921 compared
with never-smokers. We also found that one set of speciﬁc
methylation markers showed a gradual reversal of methylation
levels from those typical of current smokers to those of never-
smokers, whereas other smoking-related CpG sites’ methylation
markers remained stable more than 30 years after quitting9. These
ﬁndings are also consistent with other recent studies reporting
methylation levels in smoking-related CpG loci in former
smokers to vary based on their time since quitting21,22.
Although these previous studies have provided convincing
evidence of an association between tobacco exposure and
methylation of speciﬁc CpG sites, it is not known whether
methylation levels at some of these sites translate into increased
risk of smoking-related cancers, such as lung cancer. Here, we
present the results of an epigenome-wide methylation study based
on methylation detection using Illumina Inﬁnium HM450
on DNA extracted from pre-diagnostic blood of 132 pairs of
lung cancer cases and controls from the NOWAC cohort
(discovery set). We replicated the ﬁndings in three prospective
studies, the Melbourne Collaborative Cohort Study (MCCS; 367
cases and 367 matched controls), the Northern Sweden Health
and Disease Study (NSHDS; 234 cases and 234 matched controls)
and the EPIC Heidelberg Study (EPIC HD; 63 cases and 63
matched controls; validation sets), with adjustment for smoking
habits. To our knowledge, this is the ﬁrst study performing a
genome-wide methylation analysis to evaluate the importance of
epigenetic alterations in peripheral blood DNA to lung cancer
aetiology.
Results
Discovery set. Incident lung cancer cases in the discovery set
(NOWAC) were identiﬁed through linkage with the Cancer
Registry of Norway, with virtually complete coverage. In the
nested case–control study, lung cancer cases were diagnosed on
average 3.88 years after recruitment (range: 0.29–7.92 years) and
the mean age at diagnosis was 56 years (range: 47–64 years).
The odds ratio for lung cancer was 7.38 for former and current
smokers grouped together (95% conﬁdence interval (CI)
3.99–16.66), 6.16 (95% CI: 2.65–15.13) for former smokers and
10.13 (95% CI: 4.56–24.23) for current smokers.
Table 1 shows the top-ranked CpG sites for the locus-by-locus
epigenome-wide risk analysis, and includes all CpG sites with
Bonferroni-corrected P-values below 0.05. All top-ranked CpGs
showed inverse associations with risk, indicating hypomethyla-
tion in cancer cases. Supplementary Table 1 shows the main
information about involvement in cancer pathways for the probes
listed in Table 1: for all the CpGs except two (cg02451831 and
cg03898802) there is evidence of involvement in cancer pathways.
CpGs in the AHRR and F2RL3 genes displayed the most
signiﬁcant associations with risk consistent with previous
observations of smoking being associated with reduced
methylation in healthy subjects1–9. In the following analyses, we
exclusively focus on these two genes from Table 1, because they
are the only ones strongly associated with smoking. In particular,
the cg05575921 probe in the AHRR gene emerged as the CpG
site most strongly associated with both tobacco exposure9
and lung cancer risk (odds ratio (OR) for lung cancer per 1
standard deviation (s.d.) of beta: 0.37, 95% CI: 0.31–0.54,
P-value¼ 3.33 10 11). Sensitivity analyses excluding cases
with time from blood collection to diagnosis of o2 years
showed no signiﬁcant differences in effect estimates (OR: 0.36,
95% CI: 0.27–0.52 for cg05575921 and OR: 0.40, 95% CI: 0.29–
0.56 for cg03636183). Supplementary Table 2 shows the results of
the analyses stratiﬁed by time to diagnosis (less and more than 5
years). Associations were slightly stronger for o5 years to
diagnosis but these were unlikely to reﬂect reverse causation as
they were also evident for more than 5 years to diagnosis.
Table 2 shows the results for the probes associated with cancer
risk in the AHRR and F2RL3 genes after adjustment for smoking
(for example, smoking status coded as never, former, current):
the overall association remained basically unchanged (OR for
1 s.d.¼ 0.39, 95% CI: 0.24–0.61, P-value¼ 2.55 10 5 for
cg05575921 and OR for 1 s.d.¼ 0.51, 95% CI: 0.35–0.73,
P-value¼ 4.19 10 4 for cg03636183).
Validation sets. To validate our results arising from the NOWAC
study, we analysed the cg05575921 and cg03636183 probes in
three independent samples: a case–control study nested within
MCCS including 367 case–control pairs, a case–control study
Table 1 | Top-ranked CpG sites for the locus-by-locus risk analysis in NOWAC data (discovery set): CpGs in the AHRR and F2RL3
genes display the most signiﬁcant inverse associations with risk (hypomethylation in cases).
Probe name Gene name Chromosome Position Region OR for 1 s.d. 95% CI P-value P-value Bonferroni
cg05575921 AHRR 5 373378 N_Shore 0.37 0.31–0.54 3.33 10 11 1.36 10 5
cg03636183 F2RL3 19 17000585 N_Shore 0.40 0.31–0.56 3.86 10 10 1.58 104
cg21566642 2 233283329 Island 0.36 0.23–0.48 1.33 109 5.43 104
cg06126421 6 233284934 0.41 0.25–0.49 1.52 10 9 6.21 104
cg25305703 CASC21 8 233284402 0.45 0.35–0.60 3.28 10 8 1.34 10 2
cg21161138 AHRR 5 399360 0.46 0.36–0.62 5.01 10 8 2.04 10 2
cg01940273 2 26578098 Island 0.44 0.33–0.60 5.21 10 8 2.13 10 2
cg02451831 KIAA0087 7 30720080 0.43 0.29–0.57 6.55 108 2.67 10 2
cg05951221 2 233284661 Island 0.41 0.30–0.58 8.59 10 8 3.51 10 2
cg04884171 BOLA2 16 128378218 S_Shelf 0.33 0.15–0.41 1.18 10 8 4.82 10 2
cg03898802 DOPEY2 21 37617652 Island 0.37 0.29–0.57 1.20 10 7 4.90 10 2
CI, conﬁdence interval; OR, odds ratio.
Unconditional logistic regression models were used with DNA methylation levels included as an independent variable and were adjusted for matching variables, micro-array, position of the sample on the
micro-array and blood cell composition differentials.
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nested within the NSHDS including 234 case–control pairs and a
case–control study nested within the EPIC HD cohort, including
63 case–control pairs, all of which were matched on smoking
status (see Methods for details).
Consistent with the results from the NOWAC study, methyla-
tion levels in the MCCS, NSHDS and EPIC HD studies were
clearly inversely associated with lung cancer risk for both the
cg05575921 and cg03636183 CpG sites. The overall OR estimates
were slightly weaker in MCCS than in NOWAC (OR: 0.62, 95%
CI: 0.50–0.78, P¼ 2.91 10 5 for cg05575921 and OR: 0.70,
95% CI: 0.58–0.85, P¼ 2.21 10 4 for cg03636183), but more
comparable in NOWAC to NSHDS and EPIC HD (OR: 0.42, 95%
CI: 0.30–0.58, P¼ 2.06 10 7 for cg05575921 and OR: 0.61,
95% CI: 0.47–0.79, P¼ 1.56 10 4 for cg03636183 in NSHDS;
OR: 0.45, 95% CI: 0.22–0.92, P¼ 2.95 10 2 for cg05575921
and OR: 0.62, 95% CI: 0.38–1.04, P¼ 7.02 10 2 for
cg03636183 in EPIC HD; Table 2). We note that some
attenuation of the overall NOWAC OR estimates is expected
as MCCS, NSHDS and EPIC HD studies were matched by
smoking status.
Risk prediction model for lung cancer. We applied to the
NOWAC cohort a prediction model including smoking status
(coded as never, former, current) and methylation as a covariate.
This was not feasible for the other cohorts because of matching by
smoking. The area under the curve (AUC) of the model increased
from 0.71 to 0.76 when adding AHRR-methylation and F2RL3-
methylation as categorical variables (above or below the median)
and to 0.78 when adding the two as continuous variables.
Lung cancer risk by categories of smoking exposure. To further
evaluate the associations of the cg05575921 and cg03636183 CpG
sites with lung cancer risk, we conducted stratiﬁed risk analysis by
categories of smoking status. We found little support for an
association being present for never smokers for either CpG site,
and the associations were clearly inﬂuenced by smoking.
A notable observation regarding ever smokers was that the
association appeared to be stronger for former smokers than for
current smokers. For instance, in the NOWAC study, the OR for
the cg05575921 site was 0.23 (95% CI: 0.10–0.56) for former
smokers, and 0.46 (95% CI: 0.24–0.88) for current smokers. This
pattern was evident also in MCCS, NSHDS and EPIC HD for
both the cg05575921 and cg03636183 CpG sites (Table 2).
Methylation of AHRR and F2RL3 genes in former smokers.
The associations between smoking cessation and the mean
methylation levels in the cg05575921 probe (AHRR gene) and the
cg03636183 probe (F2RL3 gene) in NOWAC are shown in Fig. 1.
After smoking cessation, methylation levels increase and after 10
Table 2 | Results of the lung cancer risk analysis for the AHRR and F2RL3 gene probes after strict adjustment for smoking in the
discovery set and in the validation sets.
NOWAC MCCS
ca co OR 95% CI P-value ca co OR 95% CI P-value
AHRR cg05575921
Unadjusted 125 125 0.37 0.31–0.54 3.33 10 11
Adjusted* 124 122 0.39 0.24–0.61 2.55 1005 367 367 0.62 0.50–0.78 2.91 10 5
Never 11 54 0.90 0.26–3.10 8.70 1001 43 43 0.63 0.24–1.64 3.47 10 1
Formerw 41 33 0.23 0.10–0.56 1.00 1002 153 153 0.48 0.31–0.75 1.45 10 3
Currentz 72 35 0.46 0.24–0.88 1.90 1002 164 164 0.75 0.56–0.99 4.13 10 2
F2RL3 cg03636183
Unadjusted 125 125 0.40 0.31–0.56 3.86 10 10
Adjusted* 124 122 0.51 0.35–0.73 4.19 1004 367 367 0.70 0.58–0.85 2.21 104
Never 11 54 1.07 0.29–4.00 9.20 1001 43 43 0.78 0.44–1.36 3.73 10 1
Formerw 41 33 0.25 0.35–0.55 1.00 1003 153 153 0.70 0.50–0.98 3.81 10 2
Currentz 72 35 0.55 0.32–0.94 3.00 1002 164 164 0.81 0.61–1.06 1.18 10 1
NSHDS EPIC HEIDELBERG
ca co OR 95% CI P-value ca co OR 95% CI P-value
AHRR cg05575921
Unadjusted
Adjusted* 234 234 0.42 0.30–0.58 2.06 10 7 63 63 0.45 0.22–0.92 2.95 1002
Never 26 26 1.96 0.40–9.68 1.10 10 1
Formerw 70 70 0.27 0.12–0.61 1.70 10 3 16 16 0.06 0.00–2.23 1.26 1001
Currentz 120 120 0.47 0.31–0.72 5.40 104 47 47 0.56 0.27–1.16 1.16 1001
F2RL3 cg03636183
Unadjusted
Adjusted* 234 234 0.61 0.47–0.79 1.56 104 63 63 0.62 0.38–1.04 7.02 1002
Never 26 26 1.38 0.51–3.73 5.20 10 1
Formerw 70 70 0.45 0.26–0.80 6.60 10 3 16 16 0.29 0.03–3.24 3.17 1001
Currentz 120 120 0.70 0.49–0.98 3.70 10 2 47 47 0.64 0.36–1.12 1.17 1001
ca, case; CI, conﬁdence interval; co, control; MCCS, Melbourne Collaborative Cohort Study; OR, odds ratio.
*In NOWAC, the estimates are from the unconditional logistic regression models adjusted for smoking status coded as never, former, current; in MCCS, the estimates are from the conditional logistic
regression models where controls were matched on age, sex, date of blood collection, country of birth, type of biospecimen and smoking status as described in the text; in NSHDS, estimates are from
conditional logistic regression models where cases and controls were matched on age, sex, smoking status and smoking quantity; in EPIC HD, the estimates are from conditional regression models where
cases and controls were matched on smoking status and packyears of smoking.
wIn MCCS and EPIC HD, the estimates are also adjusted for number of cigarettes smoked, duration of smoking and time since quitting smoking; in NSHDS, estimates are also adjusted for duration of
smoking and time since quitting smoking.
zIn MCCS and EPIC HD, the estimates are also adjusted for number of cigarettes smoked and duration of smoking; in NSHDS, estimates are also adjusted for duration of smoking.
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years since quitting appear to approach those of never smokers.
This is consistent with the well-documented observation that
the risk of lung cancer decreases substantially after smoking
cessation.
The effect of smoking (never versus former versus current;
time since quitting smoking; smoking duration) on methylation
beta levels for cg05575921 and cg03636183 in MCCS and in
NSHDS are shown in Fig. 2. Similar to what we observed in
NOWAC (Fig. 1), in MCCS and NSHDS, methylation levels
in current smokers were lower than methylation levels in never
smokers and in former smokers the levels approached those of
never smokers with increasing time since cessation.
Comparison of the study groups. Supplementary Table 3 shows
a summary of the key characteristics of the study groups. The
limitation to a single gender in NOWAC prevented us from
making straightforward comparisons between the estimated
associations and from investigating differences in lung cancer risk
between genders. On the other hand, matching by smoking in
MCCS, NSHDS and EPIC HD did not allow us (i) to investigate
further the role of methylation as a mediator of the association
between smoking and cancer in these cohorts and (ii) to test
interactions between smoking variables such as duration or dose.
A future goal will be to repeat the analysis in unrestricted
population cohorts.
Correlation between methylation and expression. We
investigated the correlation between methylation and expression
of the two relevant probes using two different sources of data:
TCGA (http://cancergenome.nih.gov/) and HapMap (http://
hapmap.ncbi.nlm.nih.gov/). In TCGA, we focused on expression
(RNA-Seq experiments) and methylation (Illumina Human-
Methylation450 BeadChip) of samples of normal tissue
(i) from 21 lung adenocarcinoma cases (LUAD—21 methylation-
expression pairs) and (ii) from 8 lung squamous cell carcinoma
cases (LUSC—8 methylation-expression pairs). AHRR-probe
methylation seems to be signiﬁcantly inversely correlated
with AHRR expression in LUAD and the same trend was
found in LUSC (Pearson’s correlation coefﬁcient¼  0.66,
P valueo0.01 in LUAD; Pearson’s correlation coefﬁcient¼  0.43,
P value¼ 0.29 in LUSC). F2RL3-probe methylation did not show
a statistically signiﬁcant methylation-expression correlation.
Regarding HapMap, we focused on expression (RNA-Seq
experiments) and methylation (Illumina HumanMethylation27
BeadChip) data from lymphoblastoid cell lines of 69 HapMap
Yoruba individuals. In this case, only the F2RL3-probe is present
on the platform and its methylation seems to be signiﬁcantly
inversely correlated with F2RL3 expression (Pearson’s correlation
coefﬁcient¼  0.28, P valueo0.01).
Mediation analysis. Although the results described above from
the analysis of a discovery set and three validation sets seem to
provide evidence that hypomethylation of the cg05575921 and
cg03636183 probes is associated with both tobacco exposure
and lung cancer risk, the key question is whether their
hypomethylation is involved in the causal pathway, or whether
they are simply epiphenomena of smoking habits (that is, the
association of DNA methylation with lung cancer risk is
confounded by smoking). To bring some clarity to this question,
we used mediation analysis to quantify the amount by which
cg05575921 (AHRR gene) and cg03636183 (F2RL3 gene)
methylation might mediate the effect of smoking on lung cancer
incidence. This was performed for the NOWAC study as such an
analysis was not possible for the MCCS, NSHDS or EPIC HD
because of matching by smoking status.
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ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10192
4 NATURE COMMUNICATIONS | 6:10192 | DOI: 10.1038/ncomms10192 | www.nature.com/naturecommunications
We detected statistically signiﬁcant results for both
components of mediation analysis, the natural direct effect
(NDE) of smoking on lung cancer (that is, not mediated) and the
natural indirect effect (NIE, that is, the effect mediated by the
methylated probe(s)), the two together making up the total causal
effect (TCE; see Methods and Table 3, where the underlying
identifying assumptions are also stated). The proportion of the
smoking-induced risk increase explained by cg05575921
AHRR-probe was found to be B31% (0.31, 95% CI: 0.18–0.46)
and 32% (0.32, 95% CI: 0.20–0.53) for the cg03636183
F2RL3-probe. Considering the two genes together, their methyla-
tion appeared to mediateB37% (0.37, 95% CI: 0.19–0.66) of the
total effect of smoking on lung cancer odds (Fig. 3 and Table 3).
The results of mediation analysis were similar when we included
the mean methylation of a group of ten AHRR (cg05575921,
cg03991871, cg12806681, cg23916896, cg01899089, cg26703534,
cg14817490, cg25648203, cg21161138 and cg24090911) and two
F2RL3 probes (cg03636183 and cg04259305) located in the body
of the gene and signiﬁcantly associated with lung cancer after
false discovery rate correction (data not shown). In conclusion,
this analysis suggests (i) that methylation of the smoking-related
AHRR and F2RL3 CpG sites might be relevant to lung cancer
aetiology and (ii) would explain approximately one-third of the
risk increase induced by tobacco exposure.
Discussion
Tobacco smoking is one of the most important carcinogenic
exposures, and continuing smokers experience up to 25% lifetime
risk of developing a smoking-related cancer—particularly lung
cancer—yet the underlying mechanisms by which tobacco
carcinogens act on lung cells have been elusive. Mutations,
cell proliferation and selection have been hypothesized as
complementary mechanisms23,24. Epigenetics has recently
emerged as a promising ﬁeld to illuminate carcinogenetic
mechanisms23 and we have previously shown that smoking is
associated with hypomethylation in CpGs of key genes9. Here,
we present data from four prospective cohort studies that
convincingly demonstrate that hypomethylation in speciﬁc CpG
sites of the AHRR and F2RL3 genes is associated with increased
risk of subsequent lung cancer. Although we detected 11 CpG
sites in the discovery set that were associated with lung cancer, we
selected the AHRR and F2RL3 genes because of their strong
Table 3 | Mediation analysis of the NOWAC cohort based on
g-formula.
Log OR s.e. P-value 95% CI
AHRR-cg05575921
TCE 1.83 0.29 o0.001 (1.37–2.64)
NDE 1.26 0.31 o0.001 (0.75–2.08)
NIE 0.56 0.08 o0.001 (0.39–0.73)
Effect mediated 0.31 0.08 o0.001 (0.18–0.46)
F2RL3-cg03636183
TCE 1.82 0.30 o0.001 (1.29–2.48)
NDE 1.23 0.33 o0.001 (0.63–1.93)
NIE 0.59 0.09 o0.001 (0.43–0.80)
Effect mediated 0.32 0.08 o0.001 (0.20–0.53)
AHRR-cg05575921 and F2RL3-cg03636183
TCE 1.79 0.30 o0.001 (1.28–2.53)
NDE 1.13 0.34 0.001 (0.49–1.86)
NIE 0.66 0.15 o0.001 (0.42–1.09)
Effect mediated 0.37 0.11 0.001 (0.19–0.66)
CI, conﬁdence interval; NDE, natural direct effect; NIE, natural indirect effect; OR, odds ratio;
TCE, total causal effect.
TCE, NDE and NIE for the cg05575921 probe in AHRR, for the cg03636183 probe in F2RL3 and
for the two probes combined: 31% of the total effect of smoking on lung cancer risk is mediated
by AHRR site-speciﬁc methylation, 32% of the total effect of smoking on lung cancer risk is
mediated by F2RL3 site-speciﬁc methylation and 37% of the total effect of smoking on lung
cancer risk is mediated by the combined contribution of AHRR and F2RL3 methylation (separate
pathways for the two probes).
AHRR-cg05575921 methylation 
AHRR-cg05575921 methylation
F2RL3-cg03636183 methylation 
F2RL3-cg03636183 methylation 
Smoking
Smoking Smoking Lung cancer
Lung cancer
Lung cancer
Age
Age
Age
Model A
Model C
Model B
Indirect effect (that is the effect mediated by the CpG sites)
Direct effect (that is not mediated)
Figure 3 | Mediation analysis: graphical representation. In model A, the percentage of the effect mediated by AHRR-cg05575921 is B31% of the
total effect of smoking on lung cancer risk, whereas in model B, the percentage mediated by F2RL3-cg03636183 is B32%. The joint mediation
effect of these two CpGs is 37% if the two mediators are included together in the model with separate pathways (model C).
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association with smoking found in previous studies, and because
our aim was to test whether methylation may feature in the
pathway from smoking to lung cancer. AHRR is the repressor of
the aryl hydrocarbon receptor, a key regulator of the relationships
between the cell and the external environment, including the
effects of stressors such as dioxins and polycyclic aromatic
hydrocarbons (that are contained in tobacco smoke)25. AHRR is
expressed in all tissues, where it controls cell proliferation
and apoptosis; it is upregulated and epigenetically modiﬁed in
lung alveolar macrophages of smokers1. We have previously
investigated the lung tissue of smokers and non-smokers:
methylation levels in the AHRR gene probes were signiﬁcantly
lower (Po0.001) with a concurrent increase in AHRR expression
(P¼ 0.005) in the lung tissue of current smokers compared with
non-smokers7. This was further validated in a mouse model of
smoke exposure7.
F2RL3 is also a functionally relevant gene. It encodes the
protease-activated receptor-4, which has been suggested to be
involved in the pathophysiology of both cardiovascular and
neoplastic diseases26. A recent study reported that
hypomethylation of F2RL3 is predictive of total mortality and
the authors suggested that the adverse health effects of smoking
might be mediated in part by pathways related to F2RL3
methylation26.
The main question arising from our previous studies of healthy
subjects was whether methylation changes in the AHRR and
F2RL3 genes are causally involved in lung cancer aetiology by
mediating the risk induced by tobacco smoking. Although it is
not possible to fully answer this question based on our data, our
results are consistent with the notion of a mediating role. We
have observed (i) that data from multiple independent study
populations have conclusively established an association between
tobacco smoking and AHRR and F2RL3 methylation, and (ii) that
these methylation sites are also associated with lung cancer risk
after adjustment for smoking habits and with careful mediation
analysis. Although it is possible that residual confounding from
tobacco smoking might still explain the association with risk, we
note that the attenuation in OR estimates when adjusting for
smoking is negligible in all four studies. Should residual
confounding from tobacco smoking explain our observed
associations, we would expect a notable attenuation of OR
estimates in adjusted risk models. In addition, the observation
that smoking-associated hypomethylation in these speciﬁc CpG
sites is reversible following smoking cessation is compatible with
the gradual decrease in lung cancer risk that former smokers
experience. A full evaluation of the causal relevance of AHRR and
F2RL3 methylation in lung cancer aetiology requires additional
investigations, such as a Mendelian randomization analysis
of a sufﬁciently powered study27. Hypomethylation of certain
CpG sites/genes, which extends beyond smoking cessation for
several years, as observed for the two probes identiﬁed in this
study, might be more closely associated with lung cancer risk than
transient hypomethylation. In previous analyses of healthy
subjects9, we generally observed a relatively rapid reversal of
smoking-related methylation changes, but for a group of probes
including cg05575921 and cg03636183 reversal is slower or
not apparent even after decades. A larger study is required to
evaluate whether reversal of methylation alterations in
cg05575921 and cg03636183 occurs at the same rate as the
decrease in the risk of lung cancer in former smokers. Also, future
prediction models will be built based on a larger number of
cohorts not matched by smoking habits (work in preparation). In
the present study, we were able to build such a model only for the
NOWAC cohort, and there was a modest increase in prediction
(AUC changing from 0.71 to 0.78 when methylation information
was added).
Hypomethylation persists in some CpG sites for much longer
than the average half-life of circulating white-blood cells,
suggesting that stem cells (in the bone marrow in the case of
white blood cells, and hypothetically also in the lung1) may
preserve a ‘memory’ of past exposures in the form of a greater
proportion of unmethylated CpG sites versus methylated CpG
sites. We speculate that exposure to toxic agents leads to clonal
expansion of cells that are hypomethylated in CpGs of genes
involved in activation of a pathway reactive to environmental
insults, and this imbalance in the proportion of methylated DNA
in stem cells persists, remaining mitotically stable through
subsequent cell divisions.
The association of hypomethylation at the two selected CpG
sites with lung cancer was nominally stronger for former than for
current smokers in all our studies but this observation could be
due to chance or residual confounding by factors related or
unrelated to smoking.
In conclusion, our study shows that smoking-induced
hypomethylation in the AHRR and F2RL3 genes is associated
with important risk increases of subsequent lung cancer, and
indicates that these speciﬁc methylation alterations may mediate
the carcinogenic effect of tobacco exposure in lung cancer
aetiology.
Methods
Discovery set. Lung cancer cases and matched controls were identiﬁed within the
Norwegian NOWAC longitudinal cohort. The biobank of the NOWAC cohort was
collected in the years 2003–2006. Random samples of Norwegian women were
mailed a letter of information with an invitation to receive equipment for blood
sampling at the local doctor or other institutions. Those who ﬁlled in the eight-page
questionnaire and accepted the invitation to donate blood received some months
later equipment for blood drawing together with a two-page questionnaire with
information on date, lifestyle factors and so on. Around 50,000 women returned by
over-night mail two tubes of blood to the Institute of Community Medicine at
UiT–The Artic University of Norway. Upon arrival, the citrate glass tube was
centrifuged and buffy-coat and plasma frozen immediately at  80 together with a
PAXgene tube. All participants gave informed consent. The study was approved by
the Regional Committee for Medical and Health Research Ethics in North Norway.
Data storage and linkage to the National Cancer Registry of Norway were approved
by the Norwegian Data Inspectorate; follow-up identiﬁed 132 eligible cases of lung
cancer by 2011. For each case, one control with adequate blood samples was
selected matched on time since blood sampling and year of birth in order to control
for effects of storing time and ageing. The cases and the controls were kept together
through all later laboratory procedures in order to reduce any batch effects.
Validation sets. The MCCS is a prospective cohort study of 41,514 volunteers
(24,469 women) aged between 27 and 76 years at baseline (99.3% of whom were
aged 40–69 years)28. The MCCS study protocol was approved by the Cancer
Council Victoria’s Human Research Ethics. At baseline attendance, in 1990–1994,
participants completed questionnaires that measured demographic characteristics
and lifestyle factors including diet. Height and weight were directly measured and a
blood sample was collected and stored. For a large proportion of individuals (75%),
only dried blood spots on Guthrie cards were available while for others buffy coat
or lymphocyte samples were available. A total of 533 incident cases of lung cancer
identiﬁed through linkage with the State and National Cancer Registry was
diagnosed during follow-up up to the end of 2011. A total of 367 cases remained
available after excluding cases (i) diagnosed after the age of 80 years; (ii) with no
biospecimen available; (iii) with a diagnosis of any cancer before blood draw or
(iv) with no information on smoking status. The MCCS sample included 367 cases
(159 adenocarcinomas, 33 large cell cancers, 73 squamous cancers and 49 small cell
cancers) and 367 matched controls selected with a density sampling procedure.
Matching variables included sex, date of blood collection (within 6 months), date of
birth (within 1 year), country of birth (Australia and UK versus Southern Europe),
type of biospecimen (lymphocyte, buffy coat and dried blood spot) and smoking
status (never smokers; short-term former smokers: quitting smoking less than
10 years before blood draw; long-term former smokers: quitting smoking 10 years
or more before blood draw; current light smokers:o15 cigarettes per day at blood
draw; and current heavy smokers: 15 cigarettes or more at blood draw). In the
sample, the mean time between blood draw and diagnosis was 9.38 years
(s.d., 5years).
The NSHDS is an ongoing prospective cohort and intervention study intended
for health promotion in the population of Va¨sterbotten County in northern
Sweden. The study was approved by the Umeå University Ethical Committee;
details of the study population have been published previously29. Brieﬂy, study
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participants were recruited to the NSHDS in the context of the Va¨sterbotten
Intervention Project, which was initiated in 1985 to advocate a healthy diet and
lifestyle. All residents in the Va¨sterbotten County were invited to participate in the
project by attending a health check-up at 40, 50 and 60 years of age. At the health
check-up, which was held at the local health-care centre, participants were asked to
complete a self-administered questionnaire including various demographic factors
such as education, smoking habits, physical activity and diet. In addition, height
and weight were measured and participants were asked to donate a blood sample of
20ml for future research. Incident lung cancer cases were identiﬁed through
linkage to the regional cancer registry. Lung cancer cases were deﬁned on the basis
of the International Classiﬁcation of Diseases for Oncology, Second Edition
(ICD-O-2), and included all primary malignant cancers that are coded as
C34.0-C34.9 with pre-diagnostic blood samples. One control was chosen at
random for each lung cancer case from appropriate risk sets consisting of all cohort
members alive and free of cancer (except non-melanoma skin cancer) at the time of
diagnosis of the index case. Matching criteria included: date of birth (±1 year,
relaxed up to ±5 years for cases without available controls), ethnicity, gender,
date of blood collection (±1 month, relaxed up to±3 months, and further to
±6 months for cases without available controls) and detailed smoking status: never
smokers, short-term former smokers (quitting smoking less than 10 years before
blood draw), long-term former smokers (quitting smoking over 10 years before
blood draw), current light smokers (o15 cigarettes/day at blood draw) and current
heavy smokers (Z15 cigarettes per day at blood draw). After quality control, a total
of 234 incident lung cancer cases (111 adenocarcinomas, 6 large cell cancers,
47 squamous cancers, and 29 small cell cancers) and 234 individually matched
controls were available for this analysis. In the sample, the mean time from
blood draw to diagnosis was 9.6 years (range: 1.1–17.5).
The EPIC is a large multicenter cohort study of diet and chronic diseases. The
study rationale has been published previously30,31. In brief, in the EPIC Heidelberg
cohort study (EPIC HD), 25,500 study participants from the general population
were recruited from June 1994 to October 1998. Inhabitants of Heidelberg and of
the surrounding region who met the age criteria of the EPIC study design (men:
40–64 years, women: 35–64 years) were randomly invited by mail to take part in
the study. Study subjects were asked to complete questionnaires and were
interviewed about their individual health, diet and lifestyle such as life history of
tobacco smoking and alcohol intake. In addition, anthropometric measurements
were taken and a blood sample of 30ml was collected, which was fractionated and
stored in aliquots in liquid nitrogen for future research. Up to six follow-up
questionnaires were sent to the participants, at 2- to 3-year intervals, to ask about
incident diseases and changes in lifestyle and diet. All self-reported incident cases
of cancer were systematically veriﬁed against clinical and pathology records. The
present study was based on 211 incident lung cancer cases identiﬁed by July 2015.
Cases witho1 year from blood draw to diagnosis were excluded. Of the remaining
cases those with the shortest follow-up times to diagnosis and who were either
current or former smokers at the baseline recruitment were selected for this study
(n¼ 66). EPIC controls without any neoplastic disease were randomly matched to
the lung cancer cases using an incidence density protocol. Matching was done on
the basis of age at baseline (±5 years), gender, smoking status (current and
former) and pack years (±1 PY). After initial quality control, 63 incident lung
cancer cases (25 adenocarcinomas, 15 squamous cell carcinoma, 19 small-cell lung
cancer and 4 uncharacterized lung cancers) with a mean interval between blood
draw and diagnosis of 4.8 years (range: 1.1–8.6) and 63 individually matched
controls remained for further analysis. This study was approved by the ethics
committee of the Medical Faculty of the University of Heidelberg (S-627/2013).
DNA methylation measurement and data pre-processing.. Genome-wide DNA
methylation analyses were performed on pre-diagnostic blood samples using the
Illumina Inﬁnium HumanMethylation450 platform.
NOWAC laboratory procedures were carried out at the Human Genetics
Foundation (Turin, Italy), using the Illumina Inﬁnium HumanMethylation450
(HM450). Buffy coats stored in liquid nitrogen were thawed, and genomic DNA
was extracted using the QIAGEN QIAsymphony DNA Midi Kit. 500 ng of DNA
were bisulphite-converted using the Zymo Research EZ-96 DNA Methylation-Gold
Kit, and hybridized to Illumina Inﬁnium HumanMethylation450 BeadChips. These
were subsequently scanned using the Illumina HiScanSQ system, and sample
quality was assessed using control probes present on the micro-arrays. Finally, raw
intensity data were exported from Illumina GenomeStudio (version 2011.1).
MCCS laboratory procedures were carried out at the Genetic Epidemiology
Laboratory, the University of Melbourne according to manufacturers’ protocols.
DNA extraction from lymphocytes and buffy coats was performed using Qiagen
mini spin columns, whereas dried blood spot DNA was extracted using a method
developed in-house32 and the quality and quantity of DNA was assessed using the
Quant-iT Picogreen dsDNA assay measured on the Qubit Fluorometer (Life
Technologies). Samples were distributed into 96-well plates and processed in chips
of 12 arrays (8 chips per plate) with case–control pairs arranged randomly on the
same chip. All subsequent steps were performed as described above for NOWAC.
NSHDS laboratory procedures were carried out on two sites. DNA extraction
from the buffy coat of EDTA-venous blood samples was conducted at the Umeå
University, Sweden, using FlexiGene DNA Kit (QIAGEN GmbH). Illumina
Inﬁnium HumanMethylation450 BeadChip analysis was conducted at the
ALSPAC/IEU Laboratory at the University of Bristol, according to the protocol
described above for NOWAC.
EPIC HD laboratory procedures were carried out at the German Cancer
Research Center (DKFZ) and at LGC Bioscience. Buffy coat DNA was isolated at
LGC Bioscience by the company’s standardized protocols and returned to DKFZ.
DNA methylation proﬁling with the Illumina Inﬁnium HumanMethylation450
BeadChip array was performed according to the manufacturer’s instructions at the
DKFZ Genomics and Proteomics Core Facility. Quality control of genomic DNA
included three independent measurements with Quant-iT Picogreen dsDNA assay
and all samples were tested on 1% agarose gels for DNA integrity. The Zymo
Research EZ-96 DNA Methylation Kit was used for bisulﬁte conversion of DNA.
All subsequent steps were performed as described for NOWAC.
NOWAC data pre-processing was carried out using in-house software written
for the R statistical computing environment. For each sample and each probe,
measurements were set to missing if obtained by averaging intensities over less
than three beads, or if averaged intensities were below detection thresholds
estimated from negative control probes. Background subtraction (to remove
background noise) and dye bias correction (for probes using the Inﬁnium II
design) were also performed. The resulting subset of 473,929 probes targeting
autosomal CpG loci was selected for further analyses, and among these, probes
with missing values in more than 20% of the samples were excluded from the
analyses, leaving 450,890 probes. Samples with more than 5% of non-detected
probes were also excluded from the analysis (14 samples excluded).
For the MCCS, methylation data were normalized to the internal built-in
controls as provided by the standard Illumina software and subset-quantile within
array normalization for type I and II probe bias correction33. The 65 CpGs
corresponding to single-nucleotide polymorphisms were excluded. Methylation
measures were assigned as missing for CpG sites with a detection P-value higher
than 0.01. No samples failed (a sample was considered as ‘failed’ if more than 5% of
the CpG measures were missing) and 182 (0.04%) CpG sites were excluded because
values were missing for more than 20% of the samples, thus leaving 485,330 CpGs
suitable for the analysis. Only the 458 male samples were considered when ﬁltering
probes in the Y chromosome.
In the NSHDS, methylation data were normalized using a functional
normalization procedure that uses the built-in control probes to remove unwanted
technical variation34. CpG sites that mapped to multiple genomic regions were
excluded35. CpG sites with a detection P-value 40.01 were set to missing. CpG
sites were excluded if they were missing in more than 20% of samples. Samples
were excluded if more than 5% of their CpG sites were missing or if their average
detection P-value was40.01. Samples were also dropped if their case–control pair
was missing. Of 490 samples initially available, 22 were excluded on the basis of the
aforementioned procedures, leaving a total of 234 matched case–control pairs for
analysis. Methylation levels at each locus were quantiﬁed using the beta-values36.
In EPIC HD, the quality control measures included removal of SNP-containing
probes, removal of CpGs not analysed in all samples or those in non-CpG context,
correction for batch effects and normalization with beta quantile dilation method:
63 sample pairs entered the ﬁnal differential methylation analysis.
Statistical analysis. Association study. In the NOWAC study, unconditional
logistic regression models were used for all analyses, with DNA methylation levels
included as an independent variable and standardized to 1 s.d. To account for
residual technical confounding, all models were adjusted for micro-array and
position of the sample on the micro-array. All analyses were additionally adjusted
for blood cell composition differentials estimated using the algorithm developed by
Houseman et al.37 by including in the model the percentage of each cell type. The
Houseman prediction model was calibrated using DNA methylation proﬁles of
puriﬁed human leukocytes from six healthy male blood donors, and predictions
were obtained using the subset of 89,490 probes found to be differentially
methylated across cell types at a stringent Bonferroni-corrected signiﬁcance
threshold ensuring a family-wise error rate below 0.01. Further adjustment
included matching variables (year of birth, date of blood collection). Multiple
testing was accounted for by using a stringent strategy: Bonferroni correction with
control of the family-wise error rate below 0.05.
In NOWAC, we also built a predictive model based on smoking status and
methylation of AHRR and F2RL3, and estimated the AUC with and without gene
methylation. This was not feasible for the other cohorts because of matching by
smoking.
In MCCS, conditional logistic regression was applied to estimate ORs of lung
cancer. A stratiﬁed analysis by smoking status (never/former/current smokers) was
also performed with further adjustment for number of cigarettes smoked (o15,
15–24, 25 or more per day), duration of smoking (o30 years, 30–39, 40 or more)
and time since quitting (o5 years, 5–14, 15 or more). Associations between
smoking and methylation levels were assessed by ﬁtting linear-mixed effect models
with random intercepts to the M-values of methylation (M¼ log2(beta/(1-beta)))36
with three levels of clustering due to matching sets being within batch and these
within plate. The model was also controlled for the ﬁxed effects of age at blood
collection, gender and the smoking variables.
In the NSHDS, ORs for lung cancer were estimated by conditional logistic
regression. Owing to the case–control matching, all models were adjusted for age,
sex, smoking status (never/former/current smokers) and smoking quantity
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(1–14 versus414 cigarettes per day) by design. To estimate the separate effects by
smoking status, models were run separately for never, former and current smokers,
with adjustment for time since quit smoking (in former smokers only) and
smoking duration (in former and current smokers).
In EPIC HD, blood cell type composition of every sample was estimated37 using
granulocytes, CD4þ and CD8þ T cells, natural killer cells and monocytes. A
principal component analysis of the cell types was performed and the ﬁrst two
principal components were included in a linear regression model of methylation
differences for every CpG. The risk of lung cancer was then modelled using
conditional logistic regression on standardized residuals obtained from the cell type
regression, adjusting for the average number of cigarettes smoked, duration of
smoking and time since smoking cessation (for former smokers). Lung cancer risk
was investigated using the overall study population as well as for subgroups
determined by smoking status at baseline (current or former) and ORs and 95%
CIs were computed.
Mediation analysis. We performed mediation analysis to assess whether
methylation of cg05575921 (AHRR) and cg03636183 (F2RL3) probes mediated the
effect of smoking (ever smoking versus never smoking) on lung cancer risk using
parametric G-computation38 achieved by Monte Carlo simulations39 and adapted
to deal with the case–control design following VanderWeele and Vamsteelandt40.
This requires the speciﬁcation of a model for the mediator and one for the
outcome. Linear regression was used to model methylation levels as a function of
smoking status, age and their interaction, and logistic regression to model lung
cancer status as a function of age, smoking status, methylation and their
interactions. The linear regressions for methylation were weighted to account for
the study design; cases were weighted by the prevalence of lung cancer and controls
were weighted by 1 minus the prevalence.
We quantiﬁed the amount by which either or both of the two methylation
probes mediated the effect of smoking on lung cancer incidence by partitioning the
TCE of smoking into a NIE and a NDE41,42. We expressed these quantities on the
log OR scale because of the case–control design, although they can be interpreted
as log rate ratios (because cases are incident lung cancers).
The NDE is the effect of smoking on lung cancer (on the log OR scale) when
methylation takes the natural value it would have taken in the absence of smoking;
whereas the NIE quantiﬁes the change that would be found in log odds of lung
cancer for smokers if we could change their methylation level to be that of never
smokers. The TCE is the sum of these effects. The proportion of the total effect
explained by the hypothesized mechanism (proportion mediated) is given by the
ratio between NIE and TCE (on the log scale). Identiﬁcation of the mediated
proportion required structural and parametric assumptions, namely: no
unmeasured exposure-mediator, mediator-outcome and exposure-outcome
confounding; correct model speciﬁcation for each of the outcome and the
mediator(s)41,42.
In our analysis, it is possible that unmeasured confounders could lead to
inaccurate estimates of the effects: in particular, regarding exposure-mediator
confounders, information such as smoking intensity, duration of smoking and
passive smoking would probably affect the ﬁnal estimates. The ideal situation
would be to create an exposure variable that summarizes all this information and to
repeat mediation analysis using the new variable as the exposure variable. In our
case, the presence of several missing values in NOWAC data prevented us from
performing this type of analysis. Air pollution might be a confounder of the
mediator-outcome relationship, but we assumed that it would be a negligible factor
in Norway.
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